Form 4: AC Immune Director Receives Equity Awards

AC Immune SA director Renee Aguiar-Lucander was granted restricted stock units and stock options on June 11, 2026.

Summary

• Renee Aguiar-Lucander, a Director at AC Immune SA, received a grant of 16,568 restricted stock units (RSUs) on June 11, 2026, under the company's 2016 Stock Option and Incentive Plan (SOIP).
• Additionally, Aguiar-Lucander was granted options to purchase 38,889 common shares under the same plan on June 11, 2026.
• These options are set to fully vest on June 10, 2027.
• Following these transactions, Aguiar-Lucander beneficially owns 51,136 common shares, which are comprised of the underlying shares of outstanding RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine equity awards to a director rather than significant financial or strategic news.

Positives

• Director equity awards indicate alignment of management interests with shareholders.
• Grant of RSUs and stock options can incentivize long-term performance and retention.
• The reporting person is a Director, suggesting continued commitment to the company.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the granted RSUs and stock options is subject to the future performance of AC Immune SA's stock price.
• Vesting schedules for equity awards can create potential for short-term focus if not structured appropriately.

Future Outlook

The future outlook for the granted equity awards is dependent on the company's stock performance and the vesting schedule of the options.

Industry Context

StockSavvy.ai notes that the issuance of equity awards to directors is a common practice in the biotechnology and pharmaceutical sectors to align executive incentives with shareholder value and to attract and retain key talent in a competitive industry.

Stakeholder Impact

• Shareholders: The equity awards align director interests with shareholder value, potentially leading to decisions that benefit the company's stock price.
• Employees: The existence of incentive plans like the SOIP can be a positive factor for employee morale and retention, though this specific filing pertains only to a director.

Next Steps

• The stock options granted will vest on June 10, 2027.
• The reporting person will continue to hold beneficial ownership of the RSUs and underlying shares.

Key Dates

Keywords

AC Immune SA, ACIU, Form 4, Director, Equity Award, Restricted Stock Units, Stock Options, Beneficial Ownership, Securities Exchange Act